Form 4 for RANI Rani Therapeutics Holdings, Inc.
Accepted 2023-03-29 00:00:00 ET · period of report 2023-03-27 · accession 0001415889-23-005592 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-29 | 2023-03-27 | RANI | Imran Talat | CEO, Dir | A - Grant | $0.00 | +353.5K | 444.4K | +389% | $0 |
| D | 2023-03-29 | 2023-03-27 | RANI | Imran Talat | CEO, Dir | A - Grant | $0.00 | +575.6K | 575.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-03-27 | A | A | 353,500 | $0.00 | 444,445 | D | — | — | (F1) The shares subject to the restricted stock unit grant vest as follows: 1/16th of the RSUs shall vest quarterly over four years from March 27, 2023. (F2) Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-03-27 | A | A | 575,600 | $0.00 | 575,600 | D | $5.44 · — to 2033-03-26 | 575,600 Class A Common Stock | (F3) The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. |